Latest news with #CanopyGrowthCorporation
Globe and Mail
5 days ago
- Business
- Globe and Mail
Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025
Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at: About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc. , a California-based producer of high-quality cannabis extracts and clean vape technology. At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer.
Business Wire
09-07-2025
- Business
- Business Wire
Canopy Growth Appoints Tom Stewart as Interim Chief Financial Officer
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced the appointment of Tom Stewart as Interim Chief Financial Officer, effective immediately. Mr. Stewart succeeds Judy Hong, who served as Canopy Growth's Chief Financial Officer since April 2022. During her tenure, Ms. Hong played a key role in improving the Company's capital structure and significantly strengthening its financial position. Canopy Growth thanks Ms. Hong for her leadership and support of its strategic vision. Mr. Stewart is an accomplished finance executive with over 20 years of experience with public companies, including accounting, reporting, FP&A, and operational finance. He joined Canopy Growth in 2019 as Chief Accounting Officer, following 10 years in increasingly senior finance roles at Constellation Brands, Inc. Mr. Stewart began his career at PricewaterhouseCoopers and is a Certified Public Accountant in the state of New York. Mr. Stewart's appointment is part of the Company's continued execution of its Fiscal 2026 strategy, which includes a sharpened focus on operational efficiency, disciplined capital management, and building a sustainable, performance-led business. His background in performance-driven consumer packaged goods finance and accounting makes him well-suited to support Canopy Growth's financial and operational priorities in this next phase. 'Tom has been a core member of our finance leadership team and is the right person to step into this role at a critical time,' said Luc Mongeau, Chief Executive Officer. 'His background brings the right balance of financial rigor and operational insight to support our goals around efficiency, profitability, and long-term value creation.' 'I'm proud to take on this role and support Canopy Growth as we move with purpose into our next phase,' said Tom Stewart. 'I believe in the strength of this team and the long-term opportunity in the sector. My focus will be on disciplined execution, fundamentals, and building a strong financial platform as we pursue profitable growth.' The Company has initiated a formal search for a permanent Chief Financial Officer. About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc. , a California-based producer of high-quality cannabis extracts and clean vape technology. At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. For more information visit
Yahoo
24-06-2025
- Business
- Yahoo
Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for Investors
Canopy Growth Corporation (CGC) closed the most recent trading day at $1.19, moving -4.03% from the previous trading session. This move lagged the S&P 500's daily gain of 0.96%. Elsewhere, the Dow gained 0.89%, while the tech-heavy Nasdaq added 0.94%. The company's stock has dropped by 32.24% in the past month, falling short of the Medical sector's loss of 0.85% and the S&P 500's gain of 0.5%. The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.1, reflecting a 72.97% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $48.08 million, indicating a 0.64% downward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates project earnings of -$0.41 per share and a revenue of $199.33 million, demonstrating changes of +86.24% and +3.12%, respectively, from the preceding year. Investors might also notice recent changes to analyst estimates for Canopy Growth Corporation. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 22.27% higher. As of now, Canopy Growth Corporation holds a Zacks Rank of #3 (Hold). The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 164, finds itself in the bottom 34% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Wire
01-06-2025
- Business
- Business Wire
CGC Deadline: Rosen Law Firm Urges Canopy Growth Corporation (NASDAQ: CGC) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025. Canopy Growth describes itself as a company that 'produces, distributes, and sells cannabis and hemp-based products for recreational and medical purposes.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Canopy Growth Corporation (NASDAQ: CGC) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Canopy Growth had incurred significant costs producing Claybourne Co. ('Claybourne') pre-rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy Growth incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on Canopy Growth's gross margins and overall financial results; (3) accordingly, defendants had overstated the efficacy of Canopy Growth's cost reduction measures and the health of its gross margins while downplaying issues with the same; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Canopy Growth Corporation. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 3, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
30-05-2025
- Business
- Yahoo
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -840%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.76, delivering a surprise of -58.33%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Canopy Growth , which belongs to the Zacks Medical - Products industry, posted revenues of $45.3 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 9.41%. This compares to year-ago revenues of $53.99 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Canopy Growth shares have lost about 37.6% since the beginning of the year versus the S&P 500's gain of 0.5%. While Canopy Growth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Canopy Growth: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $50.6 million in revenues for the coming quarter and -$0.57 on $206.94 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Aurora Cannabis Inc. (ACB), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Aurora Cannabis Inc.'s revenues are expected to be $62.4 million, up 24.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC) : Free Stock Analysis Report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
